{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:26:07Z","timestamp":1789878367773,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.antiviral.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T02:32:38Z","timestamp":1360031558000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Chronic hepatitis B: What should be the goal for new therapies?"],"prefix":"10.1016","volume":"98","author":[{"given":"Timothy M.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cuconati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Thomas London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.01.006_b0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"Clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"EASL","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","article-title":"Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study","volume":"368","author":"Amin","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.01.006_b0015","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J","article-title":"Hepatitis B virus. The major etiology of hepatocellular carcinoma","volume":"61","author":"Beasley","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.antiviral.2013.01.006_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2013.01.006_b0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","author":"Block","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2013.01.006_b0030","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0375","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of the Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.01.006_b0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: why and how to use it in 2011 \u2013 a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0045","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1572-0241.2006.00647.x","article-title":"Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study","volume":"101","author":"Chen","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cgh.2011.08.029","article-title":"Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection","volume":"10","author":"Chen","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0055","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group.","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0060","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1073\/pnas.0603626104","article-title":"The role of cells refractory to productive infection in acute hepatitis B viral dynamics","volume":"104","author":"Ciupe","year":"2007","journal-title":"Proc. Nat. Acad. Sci."},{"key":"10.1016\/j.antiviral.2013.01.006_b0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2010.01401.x","article-title":"Is chronic hepatitis B being undertreated in the United States?","volume":"18","author":"Cohen","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"784\u2013785","key":"10.1016\/j.antiviral.2013.01.006_b0070","first-page":"787","article-title":"The emerging race to cure HIV infections","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.01.006_b0075","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMra0801644","article-title":"Hepatitis B virus infection","volume":"359","author":"Dienstag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.01.006_b0080","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00541-07","article-title":"A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion","volume":"51","author":"Dougherty","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.01.006_b0085","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1001\/archinte.160.21.3227","article-title":"Risk factors for the rising rates of primary liver cancer in the United States","volume":"160","author":"El-Serag","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.antiviral.2013.01.006_b0380","doi-asserted-by":"crossref","unstructured":"Evans, A.E., London, W.T., Gish, R.G., Cohen, C. and Block, T.M., 2012. Chronic HBV infection outside treatment guidelines: Is treatment needed? Antivir Ther. http:\/\/dx.doi.org\/10.3851\/IMP2325. [Epub ahead of print].","DOI":"10.3851\/IMP2325"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0095","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/cis391","article-title":"Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C","volume":"55","author":"Fox","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.01.006_b0100","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B infection: natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.01.006_b0105","first-page":"1","article-title":"A multidisciplinary approach to the management of hepatocellular carcinoma","volume":"6","author":"Gish","year":"2010","journal-title":"Gastroenterol. Hepatol. (NY)"},{"key":"10.1016\/j.antiviral.2013.01.006_b0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.01.006_b0120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/JVI.02008-08","article-title":"Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells","volume":"83","author":"Guo","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0130","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0135","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1478-3231.2010.02323.x","article-title":"Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma","volume":"30","author":"Hsu","year":"2010","journal-title":"Liver Int."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0140","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(11)60102-5","article-title":"100 Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees","volume":"54","author":"Lanford","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.01.006_b0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1742-1241.2012.02895.x","article-title":"New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials","volume":"66","author":"Lee","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.antiviral.2013.01.006_b0155","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","article-title":"Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed","volume":"34","author":"Lewin","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0160","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hep.24473","article-title":"Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2013.01.006_b0170","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: recent advances","volume":"26","author":"Lin","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"44","author":"Locarnini","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1440-1746.2010.06576.x","article-title":"Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?","volume":"26","author":"Lok","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0195","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/S0168-8278(11)60739-3","article-title":"737 A phase-I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single escalating oral doses of GD-9620 in healthy subjects","volume":"54","author":"Lopatin","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0200","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1440-1746.2010.06282.x","article-title":"Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients","volume":"25","author":"Ma","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0205","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1073\/pnas.0409332102","article-title":"Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection","volume":"102","author":"Mason","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.01.006_b0210","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0215","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1128\/JVI.00700-09","article-title":"Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection","volume":"83","author":"Mason","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0220","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1128\/JVI.76.11.5305-5314.2002","article-title":"Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (l-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection","volume":"76","author":"Menne","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0225","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000067914","article-title":"Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection","volume":"45","author":"Menne","year":"2002","journal-title":"Intervirology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0230","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1016\/S0168-8278(11)61116-1","article-title":"1114 Antiviral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection","volume":"54","author":"Menne","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0235","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1128\/JVI.74.10.4483-4494.2000","article-title":"Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection","volume":"74","author":"Michalak","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0240","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0245","series-title":"HepDart 2007 \u2013 Frontiers in Drug Development for Viral Hepatitis","first-page":"26","article-title":"Preclinical development of the amphipathic DNA polymer rep 9AC for the treatment of HBV infection","volume":"vol. 3","author":"Noordeen","year":"2007"},{"key":"10.1016\/j.antiviral.2013.01.006_b0250","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.23806","article-title":"Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks","volume":"52","author":"Norton","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0255","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.01.006_b0260","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.69.9.5697-5704.1995","article-title":"Detection of an RNase H activity associated with hepadnaviruses","volume":"69","author":"Oberhaus","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2009.07.015","article-title":"The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells","volume":"393","author":"Op den Brouw","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0270","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2893.2011.01533.x","article-title":"Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir","volume":"19","author":"Pan","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.01.006_b0275","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1542-3565(05)00983-3","article-title":"Chronic hepatitis B: a critical appraisal of current approaches to therapy","volume":"4","author":"Perrillo","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/523585","article-title":"Rapid virologic response: a new milestone in the management of chronic hepatitis C","volume":"46","author":"Poordad","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.01.006_b0290","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1165706","article-title":"The challenge of finding a cure for HIV infection","volume":"323","author":"Richman","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.01.006_b0385","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hep.25964","article-title":"Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?","volume":"57","author":"Seeff","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0300","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2013.01.006_b0305","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0310","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","article-title":"Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir","volume":"26","author":"Takkenberg","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"issue":"120\u2013129","key":"10.1016\/j.antiviral.2013.01.006_b0320","first-page":"e18","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0325","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0330","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0335","doi-asserted-by":"crossref","first-page":"e39179","DOI":"10.1371\/journal.pone.0039179","article-title":"PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model","volume":"7","author":"Tzeng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.01.006_b0340","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2893.2004.00523.x","article-title":"Kinetics of hepatitis B viral load during 48weeks of treatment with 600mg vs 100mg of lamivudine daily","volume":"11","author":"Wang","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.01.006_b0345","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0350","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.01.006_b0355","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.01.006_b0360","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.01.006_b0365","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: evolution over two decades","volume":"26","author":"Yuen","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.01.006_b0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","journal-title":"Gut"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T20:04:41Z","timestamp":1595361881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0166354213000211"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.01.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic hepatitis B: What should be the goal for new therapies?","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}